← Back to Company DatabaseVisit Website
Lucence
Liquid biopsy for cancer detection and treatment selection.
Series BSingaporeFounded 2016
About
Lucence is a molecular diagnostics company offering liquid biopsy tests for cancer detection and precision oncology. Its LiquidHALLMARK test provides genomic profiling from blood samples to guide treatment decisions. Based in Singapore with a global presence, the company focuses on making cancer diagnostics more accessible across Asia Pacific.
Total Funding
$70MKey Product
LiquidHALLMARK liquid biopsy testGeography
Asia PacificKey Investors
Sequoia Capital IndiaIHH HealthcareSGInnovate
Focus Areas
Early Detection / ScreeningDiagnostics
Technology
Liquid BiopsyGenomics / Sequencing
Cancer Types
LungPan-cancer
Last updated: Feb 4, 2026